We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Drug, Biotech Stock Q3 Earnings on Nov 4: MRNA, REGN & More
Read MoreHide Full Article
The third-quarter reporting cycle for the Medical sector is approaching its end. The sector comprises pharma/biotech and medical device companies.
Several big pharma companies have reported their third-quarter results so far. The results demonstrated that sales of key drugs continued to witness strong recovery during the quarter from the adverse impacts of COVID-related disruptions. The non-COVID vaccine portfolio of large pharma companies also displayed a strong recovery in demand due to the return to a more normal level of wellness visits. Bristol-Myers, Biogen, Gilead Sciences, Merck and Glaxo beat on both earnings and sales. J&J and BioMarin beat earnings estimates but missed the same for revenues. Lilly missed earnings estimates while outpacing estimates for revenues.
Per the Earnings Trends report, as of Oct 27, 25.5% of the companies in the Medical sector, constituting nearly 47.6% of the sector’s market capitalization, have reported earnings. While 78.6% beat earnings estimates, 85.7% beat the same for sales. Earnings increased 19.6% year over year on 12.1% higher revenues.
The majority of key players from the pharma space have demonstrated encouraging performance led by strong recovery in sales of newer drugs. Some of these companies also raised their guidance for 2021 based on the encouraging trend in sales growth so far. Overall, third-quarter earnings of the Medical sector are expected to rise 21.8% on a 10.5% sales increase.
Let’s analyze five pharma/drug/biotech companies set to report third-quarter 2021 results on Nov 4.
The developer of the mRNA-based COVID-19 vaccine mRNA-1273, Moderna is scheduled to report before market open.
The company’s performance has been mixed so far, with earnings beating estimates in two of the trailing four quarters and missing the same twice. It has a four-quarter negative surprise of 41.63%, on average. In the last-reported quarter, the company’s earnings beat estimates by 7.49%.
Per our proven model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
The Zacks Consensus Estimate for earnings stands at $9.01 per share. For the quarter to be reported, Moderna has an Earnings ESP of +3.59% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Our previous article showed that Moderna did not have the favorable combination to beat on earnings in the soon-to-be-reported quarter. However, estimates changed thereafter and we are more certain of a beat now.
Regeneron, which has an impressive earnings track record so far, is also scheduled to report results before market open.
The company beat earnings estimates in each of the trailing four quarters, with the average being 18.66%. In the last-reported quarter, the company’s earnings beat estimates by 11.55%. Regeneron is likely to beat estimates in the soon-to-be reported quarter as the company has an Earnings ESP of +8.78% and a Zacks Rank #1. The Zacks Consensus Estimate for earnings stands at $9.81 per share.
Regeneron’s top line is likely to have been driven by strong demand for Eylea and Dupixent during the third quarter. The antibody cocktail REGEN-COV for COVID-19 patients is likely to have brought additional revenues. (Read more: Will Eylea, Dupixent, REGEN COV Aid Regeneron Q3 Earnings?)
Regeneron Pharmaceuticals, Inc. Price and EPS Surprise
A leader in the animal health space, Zoetis, is scheduled to report results before market open.
In the last-reported quarter, the company beat earnings expectations by 10.19%. The company beat earnings estimates in each of the trailing four quarters with the average being 15.19%.
The company is likely to beat earnings estimates in the third quarter as Zoetis has an Earnings ESP of +5.46% and a Zacks Rank #3, suggesting an earnings beat. The Zacks Consensus Estimate for earnings stands at $1.10 per share.
Zoetis revenues in the last-reported quarter increased driven by higher sales of companion animal products – a trend that most likely continued in the third quarter as well. (Read more: Is a Beat in Store for Zoetis This Earnings Season?)
Novavax, which has a dismal track record so far, will release results after market close. The company missed earnings expectations by 26.33% in the last-reported quarter. It missed on earnings in each of the last four quarters, the average being -88.48%.
For the quarter to be reported, Novavax has an Earnings ESP of 0.00% and a Zacks Rank #3. The Zacks Consensus Estimate for loss stands at $4.04 per share.
The revenues during the third quarter are likely to have been driven by funding related to the development of its coronavirus vaccine candidate NVX-CoV2373. The company may provide updates on the regulatory filing timeline of the COVID-19 vaccine candidate on the upcoming earnings call. (Read more: Novavax to Report Q3 Earnings: What's in the Cards?)
Endo, which has an impressive earnings track record so far, is also scheduled to report results after market close.
The company beat earnings estimates in each of the trailing four quarters with the average being 107.07%. In the last reported quarter, the company’s earnings beat estimates by 54.76%. For the quarter to be reported, Endo has an Earnings ESP of +14.60% and a Zacks Rank #2. The Zacks Consensus Estimate for earnings stands at 46 cents per share.
Endo’s revenues are likely to have been driven by strong demand for its Specialty Products. However, the impact of the surge of COVID-19 infections during the third quarter remains to be seen.
Image: Bigstock
Drug, Biotech Stock Q3 Earnings on Nov 4: MRNA, REGN & More
The third-quarter reporting cycle for the Medical sector is approaching its end. The sector comprises pharma/biotech and medical device companies.
Several big pharma companies have reported their third-quarter results so far. The results demonstrated that sales of key drugs continued to witness strong recovery during the quarter from the adverse impacts of COVID-related disruptions. The non-COVID vaccine portfolio of large pharma companies also displayed a strong recovery in demand due to the return to a more normal level of wellness visits. Bristol-Myers, Biogen, Gilead Sciences, Merck and Glaxo beat on both earnings and sales. J&J and BioMarin beat earnings estimates but missed the same for revenues. Lilly missed earnings estimates while outpacing estimates for revenues.
Per the Earnings Trends report, as of Oct 27, 25.5% of the companies in the Medical sector, constituting nearly 47.6% of the sector’s market capitalization, have reported earnings. While 78.6% beat earnings estimates, 85.7% beat the same for sales. Earnings increased 19.6% year over year on 12.1% higher revenues.
The majority of key players from the pharma space have demonstrated encouraging performance led by strong recovery in sales of newer drugs. Some of these companies also raised their guidance for 2021 based on the encouraging trend in sales growth so far. Overall, third-quarter earnings of the Medical sector are expected to rise 21.8% on a 10.5% sales increase.
Let’s analyze five pharma/drug/biotech companies set to report third-quarter 2021 results on Nov 4.
Moderna (MRNA - Free Report)
The developer of the mRNA-based COVID-19 vaccine mRNA-1273, Moderna is scheduled to report before market open.
The company’s performance has been mixed so far, with earnings beating estimates in two of the trailing four quarters and missing the same twice. It has a four-quarter negative surprise of 41.63%, on average. In the last-reported quarter, the company’s earnings beat estimates by 7.49%.
Per our proven model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
The Zacks Consensus Estimate for earnings stands at $9.01 per share. For the quarter to be reported, Moderna has an Earnings ESP of +3.59% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Our previous article showed that Moderna did not have the favorable combination to beat on earnings in the soon-to-be-reported quarter. However, estimates changed thereafter and we are more certain of a beat now.
Moderna, Inc. Price and EPS Surprise
Moderna, Inc. price-eps-surprise | Moderna, Inc. Quote
Regeneron Pharmaceuticals (REGN - Free Report)
Regeneron, which has an impressive earnings track record so far, is also scheduled to report results before market open.
The company beat earnings estimates in each of the trailing four quarters, with the average being 18.66%. In the last-reported quarter, the company’s earnings beat estimates by 11.55%. Regeneron is likely to beat estimates in the soon-to-be reported quarter as the company has an Earnings ESP of +8.78% and a Zacks Rank #1. The Zacks Consensus Estimate for earnings stands at $9.81 per share.
Regeneron’s top line is likely to have been driven by strong demand for Eylea and Dupixent during the third quarter. The antibody cocktail REGEN-COV for COVID-19 patients is likely to have brought additional revenues. (Read more: Will Eylea, Dupixent, REGEN COV Aid Regeneron Q3 Earnings?)
Regeneron Pharmaceuticals, Inc. Price and EPS Surprise
Regeneron Pharmaceuticals, Inc. price-eps-surprise | Regeneron Pharmaceuticals, Inc. Quote
Zoetis (ZTS - Free Report)
A leader in the animal health space, Zoetis, is scheduled to report results before market open.
In the last-reported quarter, the company beat earnings expectations by 10.19%. The company beat earnings estimates in each of the trailing four quarters with the average being 15.19%.
The company is likely to beat earnings estimates in the third quarter as Zoetis has an Earnings ESP of +5.46% and a Zacks Rank #3, suggesting an earnings beat. The Zacks Consensus Estimate for earnings stands at $1.10 per share.
Zoetis revenues in the last-reported quarter increased driven by higher sales of companion animal products – a trend that most likely continued in the third quarter as well. (Read more: Is a Beat in Store for Zoetis This Earnings Season?)
Zoetis Inc. Price and EPS Surprise
Zoetis Inc. price-eps-surprise | Zoetis Inc. Quote
Novavax (NVAX - Free Report)
Novavax, which has a dismal track record so far, will release results after market close. The company missed earnings expectations by 26.33% in the last-reported quarter. It missed on earnings in each of the last four quarters, the average being -88.48%.
For the quarter to be reported, Novavax has an Earnings ESP of 0.00% and a Zacks Rank #3. The Zacks Consensus Estimate for loss stands at $4.04 per share.
The revenues during the third quarter are likely to have been driven by funding related to the development of its coronavirus vaccine candidate NVX-CoV2373. The company may provide updates on the regulatory filing timeline of the COVID-19 vaccine candidate on the upcoming earnings call. (Read more: Novavax to Report Q3 Earnings: What's in the Cards?)
Novavax, Inc. Price and EPS Surprise
Novavax, Inc. price-eps-surprise | Novavax, Inc. Quote
Endo International
Endo, which has an impressive earnings track record so far, is also scheduled to report results after market close.
The company beat earnings estimates in each of the trailing four quarters with the average being 107.07%. In the last reported quarter, the company’s earnings beat estimates by 54.76%. For the quarter to be reported, Endo has an Earnings ESP of +14.60% and a Zacks Rank #2. The Zacks Consensus Estimate for earnings stands at 46 cents per share.
Endo’s revenues are likely to have been driven by strong demand for its Specialty Products. However, the impact of the surge of COVID-19 infections during the third quarter remains to be seen.
Endo International plc Price and EPS Surprise
Endo International plc price-eps-surprise | Endo International plc Quote